Skip to main content

Table 2 Vaccine effectiveness against all-cause pneumonia, IPD and AOM

From: Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan

Serotype

PHiD-CV

PCV13

References

All-cause pneumonia

 Inpatient

23.4%

23.7%

[11]

 Outpatient

7.3%

7.3% (assumed to be the same as PHiD-CV)

[11]

IPD

 VT (10 common ST)

94.7%

94.7%

[28]

 3

0%

0%

[32] [33]

 6A

76.0% (assumed to be the same as PCV7)

94.7% (VT)

[28]

 19A

71% (base case)

19% (used in scenario analysis: worst case using Taiwan point estimate of PCV7/10)

80%

[12, 13, 34]

AOM

 AOM VT VE 10 common serotypes

69.9%

69.9%

[11]

 ST3 AOM VE

0% [10]

0%

[11]

 6A AOM VE

29.0%

69.9%

[11]

 19A

29.0%

69.9%

[11]

 NVT AOM VE

−33%

−33%

[35]

 NTHi AOM VE

21.5% [11] [0–35.3% in sensitivity analysis]

0% (based on expert opinion) [−11 to + 8% in sensitivity analysis]

[11, 35, 36]

 AOM Myringotomy

38.82%

30.6%

Estimated based on [37, 38] and overall AOM efficacies above

  1. AOM acute otitis media, IPD invasive pneumococcal disease, NTHi non-typeable Haemophilus Influenzae, NVT non-vaccine type, PCV7/13 7/13-valent pneumococcal conjugate vaccine, PHiD-CV 10-valent pneumococcal polysaccharide and NTHi protein D conjugate vaccine, ST serotype, VE vaccine effectiveness, VT vaccine-type